Precigen Valuation Multiples

Precigen Overview

About Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Founded

1998

HQ

Employees

143

Website

precigen.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $39M

EBITDA: ($75M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Precigen Financials

Precigen reported last 12-month revenue of $39M and negative EBITDA of ($75M).

In the same LTM period, Precigen generated $30M in gross profit, ($75M) in EBITDA losses, and had net loss of ($316M).

Precigen P&L

In the most recent fiscal year, Precigen reported revenue of $10M and EBITDA of ($111M).

Precigen expects next 12-month revenue of XXX and NTM EBITDA of XXX

Precigen Stock Performance

Precigen has current market cap of $2B, and enterprise value of $2B.

Precigen's stock price is $4.28.

Precigen Valuation Multiples

Precigen trades at 39.2x EV/Revenue multiple, and (20.2x) EV/EBITDA.

Precigen Financial Valuation Multiples

As of April 11, 2026, Precigen has market cap of $2B and EV of $2B.

Equity research analysts estimate Precigen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Precigen has a P/E ratio of (4.8x).

Precigen Margins & Growth Rates

Precigen's revenue in the last 12 month grew by 265%.

Precigen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.

Precigen's rule of 40 is 1109% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Precigen's rule of X is 2748% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Precigen Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Precigen M&A Activity

Precigen acquired XXX companies to date.

Last acquisition by Precigen was on XXXXXXXX, XXXXX. Precigen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Precigen Investment Activity

Precigen invested in XXX companies to date.

Precigen made its latest investment on XXXXXXXX, XXXXX. Precigen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).